Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab for refractory intestinal Behçet's disease (single-arm, open-label)
ChiCTR2100045463Phase 4Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adalimumab in Behçet's disease (BD) and gastrointestinal Behçet's disease (GI-BD), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Behçet's Disease Activity Index (DAIBD), Mucosal cure rate and 1 more. Started May 2021; status: recruiting.
02
Drugs
03
Conditions
Behçet's disease (BD)gastrointestinal Behçet's disease (GI-BD)
Beyond the preview
Go deeper on ChiCTR2100045463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045463.